Press Releases

17 September 2013

Pivotal Phase 3 Studies Initiated With APD421 in PONV

03 September 2013

Acacia Pharma Raises £15m ($23.5m) To Advance Clinical Development Of Lead Products

01 October 2012

Acacia Pharma Announces Positive Results From Phase 2a Nausea & Vomiting Study In Cancer Patients

12 May 2012

Acacia Pharma Announces Excellent Phase 2 Results For APD421 In PONV

04 January 2012

Phase 2 Study Initiated With APD421 In Post-Operative Nausea & Vomiting (PONV)

06 December 2011

Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study

25 July 2011

Phase 2 Clinical Trial Initiated With APD515 For Xerostomia

31 March 2011

Acacia Pharma Closes $10 Million Investment Round

16 February 2011

Phase 2a Clinical Trial Initiated With APD421 For Nausea & Vomiting

07 February 2011

Phase 1 Clinical Trial Completed With APD515 For Xerostomia

06 January 2011

Acacia Pharma Starts Clinical Trial With APD515 For Xerostomia

06 January 2011

New Website Launched

06 September 2010

Acacia Pharma to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development

14 December 2009

Acacia Pharma Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)

08 June 2009

Acacia Pharma Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)

31 March 2009

Acacia Pharma Initiates Phase IIa Study with APD209 in Cancer Cachexia Patients

05 February 2009

Ian Kent Appointed as Chairman

06 January 2009

Acacia Pharma Completes Clinical Trial with APD405 for Nausea & Vomiting

22 September 2008

Acacia Pharma Starts First Clinical Trial with APD405 for Nausea & Vomiting

04 March 2008

Chief Medical Officer Appointed

04 March 2008

Gilde Healthcare Investment in Acacia Pharma